You are about to be redirected to Xellia’s global website
We are now redirecting you to our global website, click ‘confirm’ below to continue or ‘cancel’ and we will return you to your previous page.
Cancel ConfirmClick here to see full
Prescribing Information
including BOXED WARNING.
According to the FDA, there is a 1 in 10 error rate associated with compounding. Many serious patient illnesses and deaths have been linked to poorly compounded drugs.3
The FDA does not evaluate compounded drugs for safety, effectiveness, or quality before they are administered to the patient. Because of this, institutions must carefully adhere to the Drug Quality and Security Act (DQSA) to avoid poorly compounded drugs that can cause potentially serious adverse events, including death.1
*According to FDA Website
Since the DSQA went into effect in 2013, the FDA has issued over 180 warning letters and recalled 150 compounded drugs. These warning letters and recalls have a direct impact on an institution's operational efficiency and ability to obtain certain drugs.1
VANCO READY®, Vancomycin Injection requires no thawing, compounding, or activating:4
When it comes to sepsis, VANCO READY® could help reduce antimicrobial lead time.
Learn MoreView the FDA guidelines for compounded drugs vs. commercially prepared products.
Learn MoreVANCO READY® Vancomycin Injection, USP is available in 7 different dose amounts to cover most of your patients' vancomycin needs.
Order VANCO READY® NOWHIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
VANCOMYCIN INJECTION, safely and effectively. See full prescribing
information for VANCOMYCIN INJECTION.
VANCOMYCIN injection, for intravenous use
Initial U.S. Approval: 1958
RECENT MAJOR CHANGES
Boxed Warning 10/2021
Warnings and Precautions, Severe Dermatologic Reactions (5.5) 5/2021
Warnings and Precautions, Potential Risk of Exposure to Excipients During the First or Second Trimester of Pregnancy (5.1) 10/2021
WARNING: POTENTIAL RISK OF EXPOSURE TO EXCIPIENTS DURING THE FIRST OR SECOND TRIMESTER OF PREGNANCY
See full prescribing information for complete boxed warning.
If use of vancomycin is needed during the first or second trimester of pregnancy, use other available formulations of vancomycin. This formulation of vancomycin injection contains the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA), which resulted in fetal malformations in animal reproduction studies at dose exposures approximately 8 and 32 times, respectively, higher than the exposures at the human equivalent dose (5.1, 8.1).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Injection and other antibacterial drugs, Vancomycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.6)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Vancomycin Injection, USP: Single-dose flexible bags containing 500 mg vancomycin in 100 mL, 750 mg vancomycin in 150 mL, 1 g vancomycin in 200 mL, 1.25 g vancomycin in 250 mL, 1.5 g vancomycin in 300 mL, 1.75 g vancomycin in 350 mL and 2 g vancomycin in 400 mL of liquid. (3)
Hypersensitivity to vancomycin (4)
WARNINGS AND PRECAUTIONSADVERSE REACTIONS
The common adverse reactions are anaphylaxis, “red man syndrome”, acute kidney injury, hearing loss, neutropenia. (6.1)